Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.52 |
| ▸ | HTR3B | O95264 | 4/20 | 0.52 |
| ▸ | HTR3A | P46098 | 4/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28269640 | 0.83 | MAPT (0.50) | TAAR1ALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL6354328 | 0.79 | CHRNB2 (0.50) | HRH1KCNH2HRH4HRH3ABCB1 | |
| SCHEMBL15244925 | 0.79 | MAPKAPK2 (0.59) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15245011 | 0.78 | ADRB1 (0.68) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL12911538 | 0.77 | HDAC2 (0.53) | HRH1KCNH2HRH4HRH3PLD1 | |
| SCHEMBL32667432 | 0.76 | SIGMAR1 (0.56) | SIGMAR1HRH3TAAR1ALDH1A1CCNC | |
| Hydrochloric Acid SCHEMBL943407 | 0.76 | HDAC2 (0.53) | HRH1KCNH2HRH4HRH3PLD1 | |
| SCHEMBL5570604 | 0.75 | ADRB1 (0.77) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Piperazine SCHEMBL3365003 | 0.74 | TAAR1 (0.50) | TAAR1ABCB1ALDH1A1USP2TSHR | |
| SCHEMBL1359864 | 0.74 | ADRB1 (0.76) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984331-B1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORP (US) | 2010-10-20 | — | — | EP | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807672-B2 | Compounds that are ERK inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1984331-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | ADRB1 2114/4885HTR3E 4390/4885HTR3B 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.